GetTopicDetailResponse(id=35e5343213, topicName=Biohaven, introduction=Biohaven, content=null, image=null, comments=3, allHits=1032, url=https://h5.medsci.cn/topic?id=3432, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=92396, tagList=[TagDto(tagId=92396, tagName=Biohaven)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2058290, encodeId=afaa205829067, content=<a href='/topic/show?id=35e5343213' target=_blank style='color:#2F92EE;'>#Biohaven#</a>, objectTitle=輝瑞和 Biohaven 獲得歐盟委員會對偏頭痛藥物 Vydura 的認(rèn)可, objectType=article, longId=299740, objectId=7dce299e40a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7dce299e40a2, replyNumber=0, likeNumber=106, createdTime=2022-11-22, rootId=0, userName=millore, userId=c0e3195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7dce299e40a2, moduleTitle=輝瑞和 Biohaven 獲得歐盟委員會對偏頭痛藥物 Vydura 的認(rèn)可, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=7dce299e40a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058289, encodeId=043d2058289b1, content=<a href='/topic/show?id=35e5343213' target=_blank style='color:#2F92EE;'>#Biohaven#</a>, objectTitle=FDA駁回了Biohaven舌下制劑治療肌萎縮側(cè)索硬化癥, objectType=article, longId=175938, objectId=450e1e5938bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=450e1e5938bf, replyNumber=0, likeNumber=92, createdTime=2019-09-11, rootId=0, userName=millore, userId=c0e3195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=450e1e5938bf, moduleTitle=FDA駁回了Biohaven舌下制劑治療肌萎縮側(cè)索硬化癥, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=450e1e5938bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058288, encodeId=3aab2058288ce, content=<a href='/topic/show?id=35e5343213' target=_blank style='color:#2F92EE;'>#Biohaven#</a>, objectTitle=Biohaven公司的髓過氧化物酶抑制劑Verdiperstat治療多系統(tǒng)萎縮癥喜獲FDA的孤兒藥指定, objectType=article, longId=160652, objectId=fb431606526e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb431606526e, replyNumber=0, likeNumber=90, createdTime=2019-10-13, rootId=0, userName=millore, userId=c0e3195, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb431606526e, moduleTitle=Biohaven公司的髓過氧化物酶抑制劑Verdiperstat治療多系統(tǒng)萎縮癥喜獲FDA的孤兒藥指定, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=fb431606526e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
